P. Momtaz

发表

Current Choices and Strategies In the Treatment of Metastatic Melanoma

M. Lacouture, P. Chapman, P. Robins, 2014 .

First-line pembrolizumab and trastuzumab in HER2-positive esophagogastric cancer

Donoghue, B. Taylor, N. Schultz, 2021 .

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

J. Wolchok, H. Maecker, A. Shoushtari, 2020, Clinical Cancer Research.

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)

J. Wolchok, A. Shoushtari, M. Callahan, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of Infusing Ipilimumab Over 30 Minutes.

J. Wolchok, M. Callahan, M. Postow, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

J. Wolchok, M. Postow, K. Panageas, 2014, Journal of Immunotherapy for Cancer.

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Allen R. Chen, H. Uno, Lee-Jen Wei, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).

J. Wolchok, A. Shoushtari, M. Callahan, 2021 .

Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment

P. Richardson, M. Wadleigh, V. Ho, 2003, Current opinion in hematology.

Neoadjuvant relatlimab and nivolumab in resectable melanoma

M. Ross, J. McQuade, J. Wargo, 2022, Nature.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Allen R. Chen, Zhezhen Jin, P. Richardson, 2002, Blood.

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

N. Schultz, C. Chong, D. Solit, 2019, Journal of Clinical Oncology.

J. Wolchok, M. Callahan, M. Postow, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

J. Wolchok, R. Shen, G. Iyer, 2021, Science Translational Medicine.

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

M. Berger, C. Iacobuzio-Donahue, D. Chakravarty, 2021, Cancer.

Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80

J. Wolchok, A. Shoushtari, M. Callahan, 2016 .

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.

J. Wolchok, A. Shoushtari, M. Callahan, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.

B. Taylor, N. Schultz, D. Solit, 2020, The Lancet. Oncology.

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

J. Wolchok, D. Coit, A. Shoushtari, 2019, Annals of Surgical Oncology.

Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia

J. Wolchok, A. Shoushtari, M. Callahan, 2020, Journal of immunotherapy.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

J. Wolchok, A. Shoushtari, M. Callahan, 2018, JAMA oncology.

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

A. Viale, J. Wolchok, D. Coit, 2017, Oncotarget.

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

J. Wolchok, D. Coit, A. Shoushtari, 2016, The oncologist.

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

N. Schultz, J. Wolchok, N. Rosen, 2021, Clinical Cancer Research.

Reply to A. Indini et al.

J. Wolchok, M. Callahan, M. Postow, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

M. Postow, P. Momtaz, 2014, Pharmacogenomics and personalized medicine.

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma.

Donavan T. Cheng, M. Berger, J. Sosman, 2017, JCO precision oncology.

Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).

J. Wolchok, A. Shoushtari, M. Callahan, 2016 .

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

J. Wolchok, A. Shoushtari, M. Hellmann, 2017, Journal of the National Cancer Institute.

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

A. Viale, O. Abdel-Wahab, D. Hyman, 2016, Oncotarget.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

M. Gönen, J. Wolchok, M. D'Angelica, 2023, Nature.

Cutaneous T-cell lymphoma: a review of current therapies and the future therapeutic implications of chemokine biology.

J. Zippin, P. Momtaz, 2009, Journal of Drugs in Dermatology.

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Zhezhen Jin, P. Richardson, E. Guinan, 2004 .

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

J. Wolchok, A. Shoushtari, M. Callahan, 2023, The oncologist.

A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.

J. Wolchok, A. Shoushtari, M. Callahan, 2020 .

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

J. Wolchok, D. Coit, A. Shoushtari, 2016, The oncologist.

Colorectal cohort analysis from the Intraperitoneal Chemotherapy After Cytoreductive Surgery for Peritoneal Metastasis (ICARuS) clinical trial.

M. Gonen, J. Guillem, G. Nash, 2023, Journal of Clinical Oncology.